Holen Sie sich die Stockscreener-App
15.31
4.65%
0.68
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.63
Offen:
$14.76
24-Stunden-Volumen:
1.52M
Relative Volume:
0.95
Marktkapitalisierung:
$1.02B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-7.3254
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
+0.72%
1M Leistung:
-24.28%
6M Leistung:
-56.26%
1J Leistung:
-64.58%
1-Tages-Spanne:
$14.76
$15.60
1-Wochen-Bereich:
$14.31
$16.30
52-Wochen-Spanne:
$14.31
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.31 | 1.01B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Tandem Diabetes Care Inc. Stock Analysis and ForecastConsistent triple returns - jammulinksnews.com
Is Tandem Diabetes Care Inc. a good long term investmentFree Stock Market Forecast Reports - jammulinksnews.com
What analysts say about Tandem Diabetes Care Inc. stockFree Investment Portfolio Suggestions - jammulinksnews.com
What drives Tandem Diabetes Care Inc. stock priceSuperior stock growth - jammulinksnews.com
Insulin Pump Market Booming with AI Integration, Attracts Focus - openPR.com
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) - Yahoo Finance
Wearable Injectors Market is expected to reach USD 24.99 billion - openPR.com
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Diabetes Devices Market is projected to grow to US$ 64.8 billion - openPR.com
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Tandem Diabetes Care stock hits 52-week low at 14.86 USD - Investing.com
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
Tandem Diabetes Care’s SWOT analysis: stock faces headwinds amid market shifts - Investing.com
Lacklustre Performance Is Driving Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 27% Price Drop - simplywall.st
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity - FinancialContent
Tandem Diabetes (TNDM) Price Target Adjusted by Leerink | TNDM S - GuruFocus
What makes Tandem Diabetes Care Inc. stock price move sharplyFree Exclusive Investment Tips - beatles.ru
Tandem Diabetes Care Inc (TNDM) Shares Decline 3.49% on July 11 - AInvest
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know - Yahoo.co
Lacklustre Performance Is Driving Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 28% Price Drop - 富途牛牛
Tandem Diabetes Care stock hits 52-week low at 15.34 USD By Investing.com - Investing.com South Africa
Tandem Diabetes Care stock hits 52-week low at 15.34 USD - Investing.com Nigeria
Tandem Diabetes Care Stock Downgraded to 'Sell' Amid Market ConcernsNews and Statistics - IndexBox
Why Tandem Diabetes (TNDM) Shares Are Sliding Today - TradingView
Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition - MSN
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes - Investing.com Canada
Citigroup Downgrades Tandem Diabetes Care to Sell From Neutral, Cuts Price Target to $14 From $24 - MarketScreener
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
(TNDM) Trading Advice - news.stocktradersdaily.com
Further weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83% - Yahoo Finance
CMS eyes competitive bidding for CGMs, insulin pumps - BioWorld MedTech
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
Why These Three Wearables Stocks Just Hit The Skids - Investor's Business Daily
Pump manufacturers: Patches are the fix for low AID uptake - BioWorld MedTech
Multiple multianalyte sensors for diabetes on horizon - BioWorld MedTech
ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors - MedTech Dive
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 + - TradingView
Tandem Diabetes (TNDM) Expands Insulin Pump Features - GuruFocus
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States | Daily Penny Alerts - FinancialContent
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - MSN
How To Trade (TNDM) - news.stocktradersdaily.com
Digital Diabetes Management Market 2025Growth in Apps, - openPR.com
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities - FinancialContent
What Does Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Indicate? - Yahoo Finance
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):